How should Journavx (suzetrigine) be used for acute moderate‑to‑severe pain in adults, including dosing, duration, contraindications, and rescue medication?

Journavx (Suzetrigine) for Acute Moderate-to-Severe Pain

Suzetrigine (Journavx) is approved for moderate-to-severe acute pain in adults at a loading dose of 100 mg followed by 50 mg every 12 hours for up to 14 days or until pain resolution, and represents the first non-opioid alternative in this new therapeutic class since 1998. 1, 2, 3

Mechanism and Clinical Profile

• Suzetrigine selectively blocks the NaV1.8 voltage-gated sodium channel, which is expressed exclusively in peripheral pain-sensing neurons and does not cross the blood-brain barrier 2, 3, 4
• This peripheral-only action eliminates central nervous system side effects including dependence, addiction, sedation, and respiratory depression that characterize opioid analgesics 2, 5, 4
• The drug demonstrates >31,000-fold selectivity for NaV1.8 compared to other sodium channel subtypes, ensuring targeted pain relief without off-target effects 2

Dosing and Administration

Standard dosing regimen: 1, 5

• Loading dose: 100 mg orally once
• Maintenance: 50 mg every 12 hours
• Duration: Up to 14 days or until pain resolution, whichever occurs first
• Administration: Take with a full glass of water; do not divide, crush, chew, or dissolve tablets 1

Pharmacokinetics

• Peak plasma concentration (Tmax) occurs approximately 3 hours after oral administration under fasting conditions 2
• Effective half-life is 23.6 hours, supporting twice-daily dosing 2
• Primary elimination occurs via hepatic metabolism 2

Clinical Efficacy

• Phase 3 trials demonstrated statistically significant and clinically meaningful pain reduction over 48 hours following abdominoplasty and bunionectomy compared to placebo 2, 5
• In a broad phase 3 single-arm study of 256 patients with surgical and non-surgical acute pain, 83.2% rated suzetrigine's effectiveness as good, very good, or excellent 5
• The drug showed efficacy across diverse acute pain conditions including postoperative pain and new-onset moderate-to-severe pain presenting to medical facilities 5

Safety and Tolerability

• Most adverse events were mild (27.7% of participants) or moderate (8.2% of participants) in severity 5
• The drug was generally safe and well-tolerated across the range of acute pain conditions studied 5
• Unlike opioids, suzetrigine does not cause euphoria, respiratory depression, or carry addiction risk due to its peripheral-only mechanism 2, 4

Special Populations

• Pediatric patients under 12 years: Not approved; consult physician 1
• Hepatic or renal impairment: Consult physician before use, as suzetrigine undergoes hepatic metabolism 1, 2

Role in Multimodal Pain Management

Suzetrigine aligns with current CDC guidelines recommending non-opioid therapies as first-line treatment for acute pain. 6, 7

• The CDC 2022 guidelines explicitly state that nonopioid therapies should be maximized before considering opioids for acute pain, with opioids reserved only when benefits clearly outweigh risks 6
• Suzetrigine provides an evidence-based alternative that addresses the critical gap between NSAIDs/acetaminophen and opioids for moderate-to-severe acute pain 7, 8
• The drug can be integrated into multimodal regimens alongside nonpharmacologic interventions (ice, heat, physical therapy) and other nonopioid pharmacologic agents 6, 2

Rescue Medication Considerations

• If suzetrigine provides inadequate pain relief, reassess the pain etiology and severity rather than automatically escalating to opioids 6
• For breakthrough pain requiring additional medication, consider optimizing the suzetrigine regimen first or adding complementary nonopioid analgesics 6
• Opioids should be reserved for severe traumatic injuries (crush injuries, burns) or invasive surgeries with expected moderate-to-severe postoperative pain when nonopioid options prove insufficient 6
• If opioids become necessary, prescribe immediate-release formulations at the lowest effective dose for the shortest duration, using as-needed rather than scheduled dosing 6

Contraindications and Precautions

• No absolute contraindications are specified in the FDA labeling, but caution is advised in patients with hepatic or renal disease given hepatic metabolism 1, 2
• The drug's peripheral-only mechanism eliminates concerns about central nervous system depression, making it safer than opioids in patients at risk for respiratory compromise 2, 5

Clinical Context and Advantages

• Suzetrigine represents the first new non-opioid analgesic approved since celecoxib in 1998, filling a critical therapeutic gap 2, 3
• Unlike NSAIDs, suzetrigine does not carry cardiovascular or gastrointestinal risks associated with COX inhibition 6
• The drug offers particular value in the current opioid crisis by providing effective analgesia without addiction potential 7, 4
• Ongoing trials are investigating suzetrigine for chronic neuropathic conditions including diabetic peripheral neuropathy 2